Home » Stocks » TLSA

Tiziana Life Sciences PLC (TLSA)

Stock Price: $2.56 USD -0.05 (-1.92%)
Updated Jun 15, 2021 4:00 PM EDT - Market closed
Pre-market: $2.46 -0.10 (-3.91%) Jun 16, 7:53 AM
Market Cap 206.04M
Revenue (ttm) n/a
Net Income (ttm) -26.13M
Shares Out 97.31M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 15
Last Price $2.56
Previous Close $2.61
Change ($) -0.05
Change (%) -1.92%
Day's Open 2.62
Day's Range 2.45 - 2.75
Day's Volume 220,393
52-Week Range 1.76 - 12.17

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION W...

2 weeks ago - GlobeNewsWire

Investment bank B Riley has restated its 'buy' advice and US$8 price target for shares in Tiziana Life Sciences PLC (LON:TILS) (NASDAQ:TLSA) after a flurry of positive news. It said safety data on key d...

2 weeks ago - Proactive Investors

Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per ADR...

2 weeks ago - Proactive Investors

Tiziana Life Sciences plc (NASDAQ: TLSA) has provided an update on further analysis of lymphocyte subsets from a Phase 1 study with nasally administered foralumab in healthy volunteers. Data showed stat...

3 weeks ago - Benzinga

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said its breakthrough fully-human monoclonal antibody “induces immunomodulatory effects capable of providing clinical benefit” when administered nasally...

3 weeks ago - Proactive Investors

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said its breakthrough fully-human monoclonal antibody “induces immunomodulatory effects capable of providing clinical benefit” when administered nasally...

3 weeks ago - Proactive Investors

NEW YORK and LONDON, May 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inf...

3 weeks ago - GlobeNewsWire

Under an individual patient expanded access program, Tiziana Life Sciences plc (NASDAQ: TLSA) has dosed the first patient with secondary progressive multiple sclerosis with nasally administered foraluma...

3 weeks ago - Benzinga

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the company's fully-human anti-...

3 weeks ago - Proactive Investors

NEW YORK and LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inf...

3 weeks ago - GlobeNewsWire

Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) said it is confident that it is well positioned to advance its drug development programs "to their next respective value inflection points". Final resu...

4 weeks ago - Proactive Investors

NEW YORK and LONDON, May 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infec...

1 month ago - GlobeNewsWire

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) announced an agreement with Takanawa Japan for a strategic business development plan to identify a clinical partner in Japan and other Asian countries. ...

1 month ago - Proactive Investors

NEW YORK and LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for on...

1 month ago - GlobeNewsWire

Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it plans to list its diagnostics business Accustem Sciences on the Nasdaq stock market in the US after its demerger and the distribution of new sto...

2 months ago - Proactive Investors

Tiziana Life Sciences plc (LON:TILS NASDAQ:TLSA) said its former subsidiary, Accustem Sciences Limited intends to list on Nasdaq. The listing will follow shortly after the completion of the distribution...

2 months ago - Proactive Investors

Tiziana Life Sciences plc (LON:TILS NASDAQ:TLSA) said its former subsidiary, Accustem Sciences Limited intends to list on Nasdaq. The listing will follow shortly after the completion of the distribution...

2 months ago - Proactive Investors

NEW YORK and LONDON, April 13, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited ("Accustem"), intends to...

2 months ago - GlobeNewsWire

Zacks Small-Cap Research has started coverage on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which is advancing three candidates for a variety of indications in autoimmune disease...

2 months ago - Proactive Investors

US investment bank B. Riley Financial has reiterated its ‘buy' advice and US$8 a share price target for Tiziana Life Sciences (NASDAQ:TLSA, LON:TILS) after a double dose of good news.

2 months ago - Proactive Investors

The FDA has allowed evaluation of Tiziana Life Sciences Plc's (NASDAQ: TLSA) nasal administration with foralumab in a secondary progressive multiple sclerosis (SPMS) patient at the Brigham and Women's H...

2 months ago - Benzinga

Shares in Tiziana Life Sciences plc (NASDAQ:TLSA, LON:TILS) shot up 20% after it announced the US regulator has approved the use of its nasally administered monoclonal antibody to treat a person with se...

2 months ago - Proactive Investors

NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infec...

2 months ago - GlobeNewsWire

Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) is taking its nasally-administered monoclonal antibody (mAB) into phase II clinical trials in people with moderate to severe Coronavirus (COVID-19). Thi...

2 months ago - Proactive Investors

Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) is taking its nasally-administered monoclonal antibody (mAB) into phase II clinical trials in people with moderate to severe COVID-19. This follows an e...

2 months ago - Proactive Investors

NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infect...

2 months ago - GlobeNewsWire

NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infec...

2 months ago - GlobeNewsWire

NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infecti...

3 months ago - GlobeNewsWire

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it is presenting at the BIO CEO & Investor Digital Conference. The conference starts today and runs until Thursday.

3 months ago - Proactive Investors

NEW YORK and LONDON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

3 months ago - GlobeNewsWire

Iconic Labs PLC (LON:ICON), a multidivisional new media and technology business, announced that it has appointed Sarah Dees as its chief executive officer and an executive director with immediate effect...

Other stocks mentioned: SLN
4 months ago - Proactive Investors

NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

4 months ago - GlobeNewsWire

Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.

4 months ago - Zacks Investment Research

NEW YORK and LONDON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncol...

4 months ago - GlobeNewsWire

NEW YORK and LONDON, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for o...

4 months ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and in...

4 months ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

4 months ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for o...

4 months ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for o...

5 months ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

5 months ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

5 months ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for o...

5 months ago - GlobeNewsWire

This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment...

5 months ago - GlobeNewsWire

LONDON and NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

5 months ago - GlobeNewsWire

NEW YORK and LONDON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inf...

6 months ago - GlobeNewsWire

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

6 months ago - GlobeNewsWire

First Ever Study with take-home capsules of Foralumab , a Fully Human Anti-CD3 Monoclonal Antibody

7 months ago - GlobeNewsWire

Tiziana Enters Human Trials for Covid-19 Treatment

YouTube video

Nov.02 -- Tiziana Life Sciences PLC is launching a clinical trial in Brazil involving humans where they will be treated with a nasally administered Foralumab, a monoclonal antibody. Gabriele Cerrone, th...

7 months ago - Bloomberg Markets and Finance

About TLSA

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), ... [Read more...]

Industry
Biotechnology
IPO Date
Mar 24, 2000
CEO
Shailubhai Kunwar
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
TLSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for TLSA stock is "Buy." The 12-month stock price forecast is 9.50, which is an increase of 271.09% from the latest price.

Price Target
$9.50
(271.09% upside)
Analyst Consensus: Buy